Compare MPLX & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPLX | NTRA |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.9B | 56.7B |
| IPO Year | 2012 | 2015 |
| Metric | MPLX | NTRA |
|---|---|---|
| Price | $57.42 | $287.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 22 |
| Target Price | $62.31 | ★ $410.26 |
| AVG Volume (30 Days) | 1.7M | ★ 1.9M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 8.46% | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,998,000,000.00 | $210,939,000.00 |
| Revenue This Year | $14.30 | $30.65 |
| Revenue Next Year | $6.79 | $21.31 |
| P/E Ratio | $11.76 | ★ N/A |
| Revenue Growth | ★ 8.92 | N/A |
| 52 Week Low | $51.60 | $181.00 |
| 52 Week High | $60.95 | $437.41 |
| Indicator | MPLX | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 48.46 | 26.33 |
| Support Level | $56.89 | $189.54 |
| Resistance Level | $57.45 | $288.04 |
| Average True Range (ATR) | 1.16 | 21.43 |
| MACD | -0.04 | -10.31 |
| Stochastic Oscillator | 40.47 | 5.81 |
MPLX is a partnership that owns pipelines and gathering and processing assets with extensive holdings in the Appalachian and Permian regions. The asset base is made up of crude oil and refined products assets dropped down from Marathon Petroleum, its sponsor, and natural gas and natural gas liquids gathering and processing assets that were purchased or built.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.